An observational study in Bone Marrow Failure and Trauma, sponsored by University Hospital, Lille. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-05.
Sponsored by University Hospital, Lille · Observational
The purpose of the study is to detect the presence of autoantibodies and autoantigens in cerebrospinal fluid early (\<48 hours) following spinal cord trauma.
The study also aims to define the central or peripheral origin of autoantibodies by looking for their simultaneous presence at the blood level and to evaluate the prognostic value of the presence of autoantibodies within the cerebrospinal fluid, as well as on the initial clinical severity than on the recovery potential.
All patients over 18 years old with spinal cord trauma, for whom CSF sampling may be performed safely within the first 48 hours.
Exclusion Criteria:
Level of anti glial fibrillary acid protein antibodies
Anti glial fibrillary acid protein antibodies measured into the cerebrospinal fluid
Time frame: The sampling is performed at the initial stage, i.e. within 48 hours after trauma. The time between trauma and sampling is specified and measured in hours.
Blood level of anti glial fibrillary acid protein antibodies
Anti glial fibrillary acid protein antibodies measured into the blood
Time frame: The sampling is performed at the initial stage, i.e. within 48 hours after trauma. The time between trauma and sampling is specified and measured in hours.
Severity of Neurological Impairment
Measured using the American Society Injury Association score
Time frame: in the initial phase, at day 7, at 1 months, 3 months, 6 months and 1 year
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is withdrawn, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Lille